Relation Between Psychoactive Drugs Overdosage and Severity of Falls in Elderly People

ConditionFall
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age75+
SponsorUniversity Hospital, Caen

About this trial

There are many epidemiological data on the relationship between the number or nature of psychoactive medications used and the risk of falling in elderly, but very little on the relationship between the amount of psychoactive medication actually present in the blood and the severity of the fall. However, the inevitable drug-drug interactions related to polypharmacy and the pharmacokinetic modifications related to old age may lead plasma overdose situations which can potentiate the risk of falls but also aggravate these consequences. The investigators therefore propose a study with the objective of verifying whether the proportion of falls with serious traumatic consequences is more frequent in patients over 75 years old, presenting plasma overdoses of psychoactive drugs (plasma concentrations higher than the usual therapeutic concentrations) in regard to those between therapeutic ranges.

The aim of this work is to verify if the falls present more severe characters when the psychoactive drug concentrations are beyond the usual therapeutic ranges.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient (male, female) aged 75 and over admitted to the emergency room for a fall and for whom hospitalization (in geriatrics or not) after going to the emergency room is planned

Patient consuming at least one psychoactive drug from the list provided in the protocol

Patient able to move before hospitalization with or without technical assistance

Patient who signed the consent

Disqualifiers

Patient not requiring hospitalization after going to the emergency room

Patient having fallen for more than 12 hours before inclusion in the study (time of sampling) [risk of excessive elimination of certain drugs with short half-lives]

Parkinsonian patient or patient who has fallen following a convulsive attack

Patient with a life-threatening prognosis in the very short term (state of shock, palliative care planned from the emergency room)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Blood sampling for psychoactive drugs dosage

    Biological/Vaccine

    4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: "overdosed" groupExperimental treatment 1 intervention
Group B: "non-overdosed" groupOther 1 intervention

Trial outcomes

Primary outcomes

1

Comparison of the percentages of falls with serious traumatic consequences in each of the two "overdosed" and "non-overdosed" groups.

To evaluate if serious traumatic consequences are more important in the group of elderly patients with plasma overdoses of psychoactive drugs than in the "non-overdosed" group.

Time frame
3 years

Secondary outcomes

1

Relationship between the category of severity of the fall (according to the criteria of Schwenk et al, 2012) and the interactions highlighted in the prescription

To evaluate influence of prescribed medication on the nature of the fall. * Prescription prior to the fall will be evaluated taking into account the drug-drug interactions. This analysis will be done taking into account the number of interactions, the effect of interactions (increase, decrease or suppression of the effect), the level of recommendations (contraindication, not recommended, precaution for use, to be taken into account). * Severity of the fall will be evaluated according to the criteria of Schwenk et al, 2012 (serious, moderate, minor or no injuries).

Time frame
3 years
2

Relationship between the blood concentrations of psychoactive drugs and the occurrence of confusional syndrome assessed by the Confusion Assessment Method and/or neurocognitive disorders assessed by the Mini Mental State Evaluation.

To evaluate influence of psychoactive drug overdosage on confusional and/or cognitive state * Blood concentrations of psychoactive drugs were measured by chromatographic methods with different unit of measure (mg/l; µg/l; mmol/l). * Confusion Assessment Method (CAM) with 3 mandatory criteria and 2 facultative criteria. * Mini Mental State Evaluation (MMSE) with total score between 0 and 30 (0 corresponding to severe impairment and 30 to no damage.

Time frame
3 years
3

Relationship between drug blood concentrations and severity of the fall, various states and functions studied during the geriatric consultation (dependence, mood, nutritional state, renal and liver function, presence of drug-drug interactions).

To evaluate the influence of psychoactive drug blood concentrations on : * severity of the fall (same criteria as in Outcome 2) * dependence, evaluated with 2 scales: Instrumental Activities of Daily Living (IADL) scale ranging 0 (indicating complete dependence) to 8 (indicating complete autonomy) and Activities of Daily Living (ADL) scale ranging 0 (indicating complete dysautonomia) to 6 (indicating complete autonomy) , * mood, evaluated with Geriatric Depression Scale (GDS) ranging 0 (as normal mood) to 15 (as high likelihood of depression) * nutritional status, evaluated with Body Mass Index (kg/m2) and albuminemia (g/L) * renal function evaluated with Chronic Kidney Disease EPIdemiology (CKD Epi) or Modification of Diet in Renal Disease (MDRD) (ml/min/1.73m2) * liver function, evaluated with liver enzymes measurement (alanine aminotransferase ALAT, aspartate transaminase ASAT IU/L), * presence of drug-drug interactions (same criteria as in Outcome 2)

Time frame
3 years
4

Comparison between psychoactive drugs identified in the blood and expected prescriptions (entry prescription)

To evaluate the level of adequacy between the prescription (expected prescriptions, verification of misuse, compliance, etc.) and the psychoactive drugs (nature and quantity evaluated as in outcome 3) found in the blood by chromatographic method.

Time frame
3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.